US free shipping over $150 · Exact worldwide rate at checkout · Crypto-only checkout guide — Shop now
T
Titan PeptideResearch-grade nasal sprays

peptides for fat loss · what the research studies · research use only

Peptides for fat loss: which ones obesity trials actually study.

Search 'best peptides for fat loss' or 'peptides for weight loss' and the discussion converges on one class: incretin-based peptides — specifically multi-receptor agonists that act on the GIP, GLP-1, and glucagon receptor systems. The compound with the strongest published human trial data in this class is retatrutide (LY3437943): a triple GIP/GLP-1/glucagon receptor agonist that produced a least-squares mean weight change of −24.2% (12 mg) and −22.8% (8 mg) versus −2.1% for placebo at 48 weeks in a Phase 2 randomised controlled trial in 338 adults with obesity (Jastreboff AM et al., NEJM 2023;389:514-526, DOI 10.1056/NEJMoa2301972, PMID 37366315). The honest framing before everything else: these are investigational compounds studied in clinical trials — they are not FDA-approved weight-loss drugs, and Titan's retatrutide is a research-use-only reagent, not for human or animal use. The second key honesty point: GH-secretagogue peptides like CJC-1295 and ipamorelin are studied for raising growth hormone and IGF-1 — they are NOT fat-loss drugs and Titan does not represent them as such. This is the class-overview funnel; for the mechanism of retatrutide specifically, see the dedicated page.

Retatrutide research reagent — $199.99 (in stock)All research peptides

Retatrutide: the largest published fat-loss trial finding in this class

Jastreboff, Kaplan and colleagues (NEJM 2023;389:514-526, DOI 10.1056/NEJMoa2301972, PMID 37366315) conducted a Phase 2 double-blind, placebo-controlled trial in 338 adults with obesity (BMI ≥30, or ≥27 with a weight-related comorbidity), randomising participants to subcutaneous weekly retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) or placebo for 48 weeks. The primary endpoint was percentage body weight change at 24 weeks. At 48 weeks: 12 mg −24.2%, 8 mg −22.8%, 4 mg −17.1%, 1 mg −8.7% vs placebo −2.1% (least-squares means). At 24 weeks, the 12-mg group had already achieved −17.5%. A weight reduction of ≥5% occurred in 92% of participants at higher doses (4 mg and above). The most common adverse events were gastrointestinal, dose-related and mostly mild-to-moderate. This is published Phase 2 science, framed as clinical trial data — not a claim about what Titan's research reagent does in a human.

Retatrutide side-effect reference →

What makes retatrutide distinct: the triple-receptor design

Retatrutide (LY3437943) is described in the NEJM 2023 paper as 'an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors' — a single peptide conjugated to a fatty diacid moiety, enabling approximately 6-day half-life and once-weekly dosing. Compared to endogenous receptor ligands, retatrutide is 8.9× more potent at the human GIP receptor, and 0.4× and 0.3× as potent at GLP-1 and glucagon receptors respectively (Jastreboff et al., NEJM 2023, Methods/Pharmacology section). GLP-1 and GIP receptor agonism reduces appetite and improves insulin sensitivity; the glucagon receptor arm is studied for its potential to increase energy expenditure via thermogenesis. Semaglutide (mono GLP-1) and tirzepatide (dual GIP/GLP-1) represent earlier members of the same class with fewer receptor targets and, in published trials, smaller weight-change magnitudes.

How does retatrutide work (mechanism page) →

The glucagon receptor arm: energy expenditure, not just appetite

What distinguishes retatrutide from dual GIP/GLP-1 agonists like tirzepatide is the addition of glucagon receptor (GCGR) agonism. A peer-reviewed 2022 Frontiers in Endocrinology review (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037, doi: 10.3389/fendo.2022.868037) reviewed the evidence that glucagon receptor activation stimulates thermogenesis in brown adipose tissue in vitro and has been associated with enhanced metabolic rate in human studies — providing a mechanism for energy-expenditure effects that complement the appetite-reduction and insulin-sensitisation effects of GLP-1 and GIP. Retatrutide's triple-agonist design is predicated on the hypothesis that co-activating all three receptor systems may produce additive or synergistic reductions in body weight beyond what GLP-1 or GIP/GLP-1 agonism achieves alone. That hypothesis is supported by the Phase 2 weight data; the mechanistic contributions of each arm in humans remain an area of active study.

Retatrutide vs tirzepatide comparison →

Semaglutide and tirzepatide: the context / class comparison

The incretin class context matters for understanding what retatrutide's trial results represent. Tirzepatide (dual GIP/GLP-1) produced approximately −22.5% weight reduction at the highest dose (15 mg) in the SURMOUNT-1 Phase 3 trial (Jastreboff et al., NEJM 2022;387:205-216). Semaglutide (mono GLP-1) produced approximately −14.9% at 2.4 mg/week over 68 weeks in the STEP 1 Phase 3 trial (Wilding et al., NEJM 2021;384:989-1002). These published trial benchmarks are frequently cited for context alongside retatrutide data — not to compare Titan products, but to show where the incretin class has been and where the triple-agonist design sits relative to prior compounds. All are investigational or approved pharmaceutical agents, not research-use-only reagents comparable to Titan's product.

Retatrutide vs tirzepatide vs semaglutide →

GH-secretagogues are NOT fat-loss peptides — the important correction

A common misconception in the 'best peptides for fat loss' genre is listing CJC-1295/ipamorelin or other GH-secretagogues as fat-loss compounds. They are not. CJC-1295 and ipamorelin are studied for raising growth hormone (GH) and IGF-1 — not for reducing fat mass in humans. There is no controlled human trial showing these peptides reduce body fat. The association runs through the GH→lipolysis pathway (GH can promote lipolysis in vitro/animal models) but the leap to 'fat-loss drug' is marketing that has run past the data. Titan stocks CJC-1295 + Ipamorelin and does not represent it as a fat-loss product. See the honest muscle-growth reference page for the accurate framing of these compounds.

What CJC-1295/ipamorelin is actually studied for →

For an acylated peptide, identity is the real quality variable

Retatrutide is an acylated peptide — a fatty diacid chain is conjugated to the peptide backbone to achieve its ~6-day half-life and enable weekly dosing. That acyl modification is a distinct structural feature that requires identity confirmation by mass spectrometry: the acylated species has a different mass from unmodified peptide, so a real lot-matched ESI-MS result is the meaningful check, not a bare HPLC purity number alone. Titan supplies retatrutide with lot-matched, in-house release documentation (HPLC purity vs internal target + ESI-MS identity confirmation of the acylated species) available on request. No third-party certificate is claimed — the honest edge is a real, lot-matched in-house release sheet.

Lot COA checklist →

The detail, in plain terms

Peptides-for-fat-loss research, at a glance.

Points below summarise published research on the compounds most discussed for fat loss / obesity. The strongest data is from the incretin/triple-agonist class — retatrutide in Phase 2 human trials, tirzepatide and semaglutide in Phase 3. GH-secretagogues are not included: they are studied for GH/IGF-1 elevation, not fat loss. Everything is published science, reproduced as research reference. Research use only; not medical or human-use advice.

Most-studied 'fat-loss' peptide class
Incretin-based multi-receptor agonists: GIP, GLP-1, and/or glucagon receptor agonists, studied in Phase 2–3 obesity trials.
Retatrutide Phase 2 (48wk, NEJM 2023)
LS-mean weight change vs placebo: 12 mg −24.2%, 8 mg −22.8%, 4 mg −17.1%, 1 mg −8.7%, placebo −2.1%. ≥5% weight loss in 92% at 4 mg+. Jastreboff et al., NEJM 2023;389:514-526, PMID 37366315.
Retatrutide at 24 weeks
12 mg group: −17.5% LS-mean weight change (primary endpoint). Phase 2 n=338 adults with obesity.
Retatrutide receptor pharmacology
Triple GIP/GLP-1/glucagon agonist; 8.9× more potent than endogenous GIP ligand at human GIP receptor; ~0.4×/0.3× at GLP-1/glucagon. Acylated; ~6-day half-life. (NEJM 2023 Methods.)
Glucagon receptor arm (energy expenditure)
GCGR agonism studied for thermogenesis in brown adipose tissue + enhanced metabolic rate in humans — the energy-expenditure arm complementing GLP-1/GIP appetite+insulin effects. (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037.)
Class context: tirzepatide (dual GIP/GLP-1)
~−22.5% at 15 mg at 72wk (SURMOUNT-1, NEJM 2022). No glucagon arm; approved pharmaceutical.
Class context: semaglutide (mono GLP-1)
~−14.9% at 2.4 mg at 68wk (STEP 1, NEJM 2021). Mono-agonist; approved pharmaceutical.
GH-secretagogues (NOT fat-loss drugs)
CJC-1295 and ipamorelin raise GH and IGF-1 — no controlled human trial shows fat-mass reduction. Not in this class. Do not conflate.
Regulatory / RUO status
Retatrutide is an investigational compound (no FDA approval). Titan's product is a research-use-only reagent, not for human or animal use. No efficacy/weight-loss claim about Titan's product.
Identity check (acylated species)
Acylated peptide: acyl-modification must be confirmed by ESI-MS. Titan: lot-matched in-house HPLC + ESI-MS identity sheet on request. No third-party COA claimed.

Questions researchers ask

Before you order.

What peptides are studied for fat loss?
The peptides with the strongest published human fat-loss trial data belong to the incretin/multi-receptor agonist class: compounds that act on the GIP, GLP-1, and/or glucagon receptors. Retatrutide (LY3437943), a triple GIP/GLP-1/glucagon receptor agonist, produced −24.2% LS-mean weight change at 48 weeks (12 mg) in a Phase 2 randomised trial in 338 adults with obesity (Jastreboff et al., NEJM 2023;389:514-526, PMID 37366315). Tirzepatide (dual GIP/GLP-1) and semaglutide (mono GLP-1) are approved pharmaceuticals with Phase 3 trial data. These are all investigational or pharmaceutical agents — distinct from research-use-only reagents. GH-secretagogues like CJC-1295 and ipamorelin are NOT fat-loss peptides; they are studied for GH/IGF-1 elevation. This is a research reference, not medical advice.
Is retatrutide the best peptide for weight loss?
In the published Phase 2 human trial data, retatrutide produced the largest LS-mean weight reductions reported for any incretin-class compound at time of publication: −24.2% (12 mg, 48 weeks) and −22.8% (8 mg, 48 weeks), versus −2.1% for placebo (Jastreboff et al., NEJM 2023). For context, tirzepatide (dual GIP/GLP-1 agonist) produced approximately −22.5% in Phase 3 SURMOUNT-1, and semaglutide (mono GLP-1) approximately −14.9% in Phase 3 STEP 1. However: retatrutide has only Phase 2 data published (Phase 3 is ongoing); it is not FDA-approved; and Titan's retatrutide is a research-use-only reagent, not a weight-loss drug. This is a clinical-trial data comparison, not a product efficacy claim.
How does the incretin peptide class cause fat loss in trials?
Incretin-class peptides act on G-protein-coupled receptors that regulate appetite and metabolic rate. GLP-1 receptor agonism reduces appetite, slows gastric emptying, and improves insulin sensitivity. GIP receptor agonism adds further effects on appetite (central potentiation of GLP-1 effects) and adipose tissue lipid handling. The glucagon receptor arm (present in retatrutide but not tirzepatide or semaglutide) is studied for potential thermogenic effects — increasing energy expenditure via brown adipose tissue activation and resting metabolic rate enhancement (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037). In a triple-agonist design like retatrutide, the combination of reduced food intake (GLP-1/GIP) and potentially increased energy expenditure (glucagon) is the mechanistic rationale for the large weight reductions seen in trials.
Do CJC-1295 and ipamorelin help with fat loss?
No — at least not by evidence. CJC-1295 and ipamorelin are GH-secretagogue peptides, studied for raising growth hormone (GH) and IGF-1 in humans (Teichman et al., J Clin Endocrinol Metab 2006; Raun et al., Eur J Endocrinol 1998). While GH can promote lipolysis through downstream mechanisms, there is no controlled human trial showing CJC-1295 or ipamorelin reduces fat mass. They are frequently mis-listed in 'best peptides for fat loss' articles — that is marketing that has outrun the data. These are research-use-only compounds studied for GH/IGF-1 pharmacology, not for obesity or fat reduction.
Is retatrutide FDA-approved for weight loss?
No. Retatrutide (LY3437943) is an investigational compound; only Phase 2 data have been published and Phase 3 trials are ongoing (as of 2026). It is not FDA-approved for any indication. Titan Peptide Lab supplies retatrutide strictly as a research-use-only reagent for in-vitro laboratory use — not for human or animal administration, and not as a weight-loss product. The trial data cited on this page is published clinical science, not a claim about what Titan's product does.
How do I know a retatrutide vial contains the correct acylated compound?
Retatrutide is an acylated peptide — a fatty diacid chain is attached to the peptide backbone, which is what produces its ~6-day half-life. A simple HPLC purity number tells you the proportion of the major peak but does not confirm whether that peak is the correctly acylated species. Identity must be confirmed by mass spectrometry: the acylated form has a distinct molecular weight from unmodified peptide. Titan provides lot-matched, in-house release documentation (HPLC purity + ESI-MS identity of the acylated species) on request. No third-party COA is claimed; the verifiable edge is a real, lot-matched in-house release sheet.

Related reading

Before you check out.